Virttu Biologics Appoints CEO
This article was originally published in Scrip
Virttu Biologics, a biotechnology company focused on developing oncolytic immunotherapies, has appointed Deirdre Y. Gillespie CEO. Gillespie has experience of working with oncolytic vectors and was CEO of privately held Oxxon Therapeutics Inc. from 2001 to 2006. She was previously president and CEO of publically held La Jolla Pharmaceutical Company and chief operating officer of Vical, Inc. Gillespie also held various positions in clinical development at Sandoz Pharma AG (Novartis) and senior strategic and commercial positions at DuPont Merck Pharmaceutical Company including vice-president of marketing.